- Barrons.com•19 hours ago
After years of skyrocketing stock prices fueled by blockbuster drug sales, Big Biotech is now seen by investors as being no better, and perhaps worse, than Big Pharma. You are getting good pipeline assets at a much bigger discount,” says Marshall Gordon, manager of the ClearBridge Global Health Care Innovations fund.
Though user base is small for this rare disease, the high annual cost of up to $2 million offers attractive commercials for Alexion.
- Business Wire•2 days ago
Alexion Pharmaceuticals, Inc. announced today that more than 1,500 employees around the world are volunteering in their respective communities as part of the Company’s first Global Day of Service.
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||127.22 x 100|
|Ask||127.49 x 100|
|Day's Range||127.18 - 132.30|
|52wk Range||110.56 - 193.45|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||319.65|
|Avg Vol (3m)||1,722,460|
|Dividend & Yield||N/A (N/A)|